Mimedx Group Stock Analysis

MDXG Stock  USD 9.22  0.16  1.77%   
MiMedx Group is undervalued with Real Value of 10.93 and Target Price of 12.06. The main objective of MiMedx stock analysis is to determine its intrinsic value, which is an estimate of what MiMedx Group is worth, separate from its market price. There are two main types of MiMedx's stock analysis: fundamental analysis and technical analysis.
The MiMedx stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and MiMedx's ongoing operational relationships across important fundamental and technical indicators.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MiMedx Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

MiMedx Stock Analysis Notes

About 68.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 2.97. MiMedx Group had not issued any dividends in recent years. The entity had 3235:10000 split on the 2nd of April 2008. MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. Mimedx operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 811 people. To find out more about MiMedx Group contact Joseph Capper at 770 651 9100 or learn more at https://www.mimedx.com.

MiMedx Quarterly Total Revenue

84.06 Million

MiMedx Group Investment Alerts

MiMedx Group appears to be risky and price may revert if volatility continues
MiMedx Group is unlikely to experience financial distress in the next 2 years
About 68.0% of the company shares are owned by institutional investors
Latest headline from zacks.com: How Much Upside is Left in MiMedx Wall Street Analysts Think 37.12

MiMedx Group Upcoming and Recent Events

27th of February 2024
Upcoming Quarterly Report
View
7th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

MiMedx Largest EPS Surprises

Earnings surprises can significantly impact MiMedx's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-10-30
2024-09-300.040.050.0125 
2023-10-30
2023-09-300.050.060.0120 
2022-11-02
2022-09-30-0.08-0.09-0.0112 
View All Earnings Estimates

MiMedx Environmental, Social, and Governance (ESG) Scores

MiMedx's ESG score is a quantitative measure that evaluates MiMedx's performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of MiMedx's operations that may have significant financial implications and affect MiMedx's stock price as well as guide investors towards more socially responsible investments.

MiMedx Thematic Classifications

In addition to having MiMedx stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Medical Equipment Idea
Medical Equipment
USA Equities from Medical Equipment industry as classified by Fama & French

MiMedx Stock Institutional Investors

Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Renaissance Technologies Corp2024-09-30
1.5 M
Royal Bank Of Canada2024-06-30
1.5 M
Charles Schwab Investment Management Inc2024-09-30
1.4 M
Northern Trust Corp2024-09-30
1.1 M
Royce & Associates, Lp2024-09-30
972.9 K
Richmond Brothers Inc2024-06-30
917.3 K
Federated Hermes Inc2024-09-30
906.8 K
Arrowstreet Capital Limited Partnership2024-06-30
903.1 K
Millennium Management Llc2024-06-30
889.4 K
Essex Woodlands Health Ventures2024-09-30
28.2 M
Blackrock Inc2024-06-30
9.3 M
Note, although MiMedx's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

MiMedx Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.33 B.

MiMedx Profitablity

The company has Profit Margin (PM) of 0.26 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.14 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.14.
Last ReportedProjected for Next Year
Return On Tangible Assets 0.31  0.33 
Return On Capital Employed 0.19  0.20 
Return On Assets 0.28  0.30 
Return On Equity 0.47  0.45 

Management Efficiency

MiMedx Group has return on total asset (ROA) of 0.1838 % which means that it generated a profit of $0.1838 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.6247 %, meaning that it created $0.6247 on every $100 dollars invested by stockholders. MiMedx's management efficiency ratios could be used to measure how well MiMedx manages its routine affairs as well as how well it operates its assets and liabilities. At this time, MiMedx's Return On Assets are most likely to increase slightly in the upcoming years. At this time, MiMedx's Total Current Assets are most likely to increase significantly in the upcoming years. The MiMedx's current Intangible Assets is estimated to increase to about 9.5 M, while Other Current Assets are projected to decrease to roughly 4.1 M.
Last ReportedProjected for Next Year
Book Value Per Share 1.23  1.29 
Tangible Book Value Per Share 1.01  1.06 
Enterprise Value Over EBITDA 24.38  25.60 
Price Book Value Ratio 7.16  6.80 
Enterprise Value Multiple 24.38  25.60 
Price Fair Value 7.16  6.80 
Enterprise Value987.8 MB
The management strategies employed by MiMedx's are designed to enhance shareholder value and ensure long-term growth. We assess the effectiveness of these strategies in our stock analysis.
Operating Margin
0.1363
Profit Margin
0.258
Beta
1.939
Return On Assets
0.1838
Return On Equity
0.6247

Technical Drivers

As of the 22nd of November, MiMedx secures the risk adjusted performance of 0.1125, and Mean Deviation of 2.24. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of MiMedx Group, as well as the relationship between them. Please verify MiMedx Group standard deviation, maximum drawdown, as well as the relationship between the Maximum Drawdown and expected short fall to decide if MiMedx Group is priced some-what accurately, providing market reflects its recent price of 9.22 per share. Given that MiMedx Group has jensen alpha of 0.5589, we recommend you to check MiMedx's last-minute market performance to make sure the company can sustain itself at a future point.

MiMedx Group Price Movement Analysis

Execute Study
The output start index for this execution was nineteen with a total number of output elements of fourty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. MiMedx middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for MiMedx Group. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

MiMedx Group Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific MiMedx insiders, such as employees or executives, is commonly permitted as long as it does not rely on MiMedx's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases MiMedx insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

MiMedx Outstanding Bonds

MiMedx issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. MiMedx Group uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most MiMedx bonds can be classified according to their maturity, which is the date when MiMedx Group has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

MiMedx Predictive Daily Indicators

MiMedx intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of MiMedx stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

MiMedx Corporate Filings

8K
18th of November 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
13A
12th of November 2024
An amended filing to the original Schedule 13G
ViewVerify
13A
8th of November 2024
An amended filing to the original Schedule 13G
ViewVerify
13A
7th of November 2024
The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934
ViewVerify
13A
4th of November 2024
An amended filing to the original Schedule 13G
ViewVerify
10Q
30th of October 2024
Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations
ViewVerify
13A
22nd of October 2024
An amended filing to the original Schedule 13G
ViewVerify
10Q
31st of July 2024
Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations
ViewVerify

MiMedx Forecast Models

MiMedx's time-series forecasting models are one of many MiMedx's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary MiMedx's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About MiMedx Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how MiMedx prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling MiMedx shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as MiMedx. By using and applying MiMedx Stock analysis, traders can create a robust methodology for identifying MiMedx entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin 0.10  0.10 
Operating Profit Margin 0.12  0.12 
Net Profit Margin 0.21  0.22 
Gross Profit Margin 0.83  0.55 

Current MiMedx Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. MiMedx analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. MiMedx analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
12.06Strong Buy5Odds
MiMedx Group current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most MiMedx analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand MiMedx stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of MiMedx Group, talking to its executives and customers, or listening to MiMedx conference calls.
MiMedx Analyst Advice Details

MiMedx Stock Analysis Indicators

MiMedx Group stock analysis indicators help investors evaluate how MiMedx stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading MiMedx shares will generate the highest return on investment. By understating and applying MiMedx stock analysis, traders can identify MiMedx position entry and exit signals to maximize returns.
Begin Period Cash Flow66 M
Long Term Debt48.1 M
Common Stock Shares Outstanding146 M
Total Stockholder Equity142.7 M
Tax Provision597 K
Quarterly Earnings Growth Y O Y-0.097
Property Plant And Equipment Net9.1 M
Cash And Short Term Investments82 M
Cash82 M
Accounts PayableM
Net Debt-33.9 M
50 Day M A6.4808
Total Current Liabilities46 M
Other Operating Expenses284.4 M
Non Current Assets Total74.8 M
Forward Price Earnings19.5313
Non Currrent Assets Other205 K
Stock Based Compensation17 M

Complementary Tools for MiMedx Stock analysis

When running MiMedx's price analysis, check to measure MiMedx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MiMedx is operating at the current time. Most of MiMedx's value examination focuses on studying past and present price action to predict the probability of MiMedx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MiMedx's price. Additionally, you may evaluate how the addition of MiMedx to your portfolios can decrease your overall portfolio volatility.
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Bonds Directory
Find actively traded corporate debentures issued by US companies
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios